Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 24 (August 20), 2008: pp. 4022-4026
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.17.7139

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Somerfield, M. R.
Right arrow Articles by Lyman, G. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Somerfield, M. R.
Right arrow Articles by Lyman, G. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SPECIAL ARTICLE

American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges

Mark R. Somerfield, Kaitlin Einhaus, Karen L. Hagerty, Melissa C. Brouwers, Jerome Seidenfeld, Gary H. Lyman

From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

Corresponding author: Mark R. Somerfield, PhD, 1900 Duke St, Alexandria, VA 22314; e-mail: Mark.somerfield{at}asco.org

The American Society of Clinical Oncology (ASCO) published its first clinical practice guideline, which focused on the use of hematopoietic colony-stimulating factors, in 1994. Since then, ASCO has published 24 additional guidelines or technology assessments on a range of topics and is developing 11 additional guidelines. Guidelines are among ASCO's most valued products, according to membership surveys and data from the JCO.org Web site. However, the same data from ASCO members have highlighted a number of limitations to the guideline program. These relate to the timelines of guideline updates, difficulties locating guidelines and related products, and challenges to implementing ASCO guidelines in everyday clinical practice. This article outlines the concrete steps that the ASCO Health Services Committee (HSC) is taking to address these limitations, including the institution of a more aggressive guideline updating schedule, a transition from narrative to systematic literature reviews to support the practice recommendations, a new Board of Directors–approved policy to permit endorsement of other groups’ guidelines, and a robust Clinical Tools and Resources program that offers a range of guideline dissemination and implementation aids. Additional work is underway to establish stronger and deeper collaborations with practicing oncologists to expand their role in the review, field testing, and implementation of guideline clinical tools and resources. Finally, the HSC is discussing evaluation of the guidelines program to maximize the impact of ASCO clinical practice guidelines on clinical decision making and, ultimately, the quality of cancer care.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch Intern MedHome page
M. D. Cabana
Adherence, Not Just for Patients: Comment on "Low Back Pain and Best Practice Care"
Arch Intern Med, February 8, 2010; 170(3): 277 - 278.
[Full Text] [PDF]


Home page
JCOHome page
G. H. Lyman and A. A. Khorana
Cancer, Clots and Consensus: New Understanding of an Old Problem
J. Clin. Oncol., October 10, 2009; 27(29): 4821 - 4826.
[Full Text] [PDF]


Home page
Ann OncolHome page
P. Hietanen
Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Ann. Onc., October 1, 2009; 20(10): 1749 - 1751.
[Full Text] [PDF]


Home page
Ann OncolHome page
I. Ray-Coquard, S. Dussart, C. Goillot, D. Mayeur, P. Debourdeau, H. Ghesquieres, T. Bachelot, A. Le Cesne, B. Anglaret, C. Agostini, et al.
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin {alpha}: a prospective randomized controlled trial of the ELYPSE study group
Ann. Onc., June 1, 2009; 20(6): 1105 - 1112.
[Abstract] [Full Text] [PDF]


Home page
J Oncol PractHome page
E. P. Balaban
Current Issues Regarding ASCO Guideline Implementation
J. Oncol. Pract, January 1, 2009; 5(1): 38 - 39.
[Full Text] [PDF]


Home page
J Oncol PractHome page
G. H. Lyman
ASCO Clinical Practice Guidelines: Past, Present and Future
J. Oncol. Pract, September 1, 2008; 4(5): 236 - 237.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online